Get the Stockscreener App
5.365
3.33%
-0.185
Abcellera Biologics Inc stock is traded at $5.365, with a volume of 1.99M.
It is down -3.33% in the last 24 hours and down -9.07% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$5.55
Open:
$5.545
24h Volume:
1.99M
Relative Volume:
0.40
Market Cap:
$1.60B
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-10.32
EPS:
-0.52
Net Cash Flow:
$-121.38M
1W Performance:
-7.02%
1M Performance:
-9.07%
6M Performance:
+122.61%
1Y Performance:
+96.52%
1-Day Range:
$5.21
$5.60
1-Week Range:
$5.21
$5.79
52-Week Range:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
150 W 4TH AVENUE, VANCOUVER
Compare ABCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
5.36 | 1.66B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.29 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.61 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.65 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.27 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.17 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Resumed | Leerink Partners | Outperform |
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
What makes AbCellera Biologics Inc. (8QQ) stock appealing to growth investorsWeekly Risk Summary & Daily Technical Forecast Reports - newser.com
Will AbCellera Biologics Inc. stock recover faster than peersQuarterly Market Summary & High Accuracy Swing Entry Alerts - newser.com
Understanding AbCellera Biologics Inc.’s price movementMarket Volume Summary & Real-Time Volume Surge Alerts - newser.com
Risk adjusted return profile for AbCellera Biologics Inc. analyzedWeekly Profit Summary & AI Driven Stock Price Forecasts - newser.com
Will AbCellera Biologics Inc. see short term momentumDollar Strength & Growth Focused Investment Plans - newser.com
Can AbCellera Biologics Inc. (8QQ) stock resist broad market declinesWeekly Trade Analysis & Low Volatility Stock Recommendations - newser.com
How to interpret RSI for AbCellera Biologics Inc. stock2025 Market Overview & Verified High Yield Trade Plans - newser.com
Will AbCellera Biologics Inc. stock maintain momentum in 2025July 2025 Highlights & Real-Time Volume Analysis - newser.com
Can volume confirm reversal in AbCellera Biologics Inc.Portfolio Update Summary & Real-Time Chart Pattern Alerts - newser.com
Is AbCellera Biologics Inc. (8QQ) stock dividend growth reliableMarket Activity Summary & Fast Moving Market Watchlists - newser.com
Is a relief rally coming for AbCellera Biologics Inc. holders2025 Performance Recap & Accurate Entry and Exit Point Alerts - newser.com
Real time breakdown of AbCellera Biologics Inc. stock performanceEarnings Overview Summary & Step-by-Step Swing Trade Plans - newser.com
What to do if you’re stuck in AbCellera Biologics Inc.July 2025 Price Swings & Consistent Growth Equity Picks - newser.com
What’s next for AbCellera Biologics Inc. stock price2025 Fundamental Recap & AI Driven Stock Reports - newser.com
What dividend safety rating applies to AbCellera Biologics Inc. (8QQ) stock2025 Volatility Report & Weekly Chart Analysis and Guides - newser.com
Will AbCellera Biologics Inc. (8QQ) stock hit Wall Street targetsWeekly Profit Recap & Capital Efficiency Focused Ideas - newser.com
AbCellera Biologics Inc. stock volume spike explained2025 Big Picture & Free AI Powered Buy and Sell Recommendations - newser.com
Is AbCellera Biologics Inc. a candidate for recovery playMarket Trend Report & Weekly Top Stock Performers List - newser.com
Is it time to cut losses on AbCellera Biologics Inc.Analyst Upgrade & Smart Allocation Stock Tips - newser.com
Using flow based indicators on AbCellera Biologics Inc.Rate Hike & Daily Growth Stock Investment Tips - newser.com
AbCellera Biologics (ABCL) to Release Quarterly Earnings on Thursday - MarketBeat
How AbCellera Biologics Inc. stock reacts to Fed rate cutsWatch List & Fast Moving Stock Trade Plans - newser.com
What earnings revisions data tells us about AbCellera Biologics Inc.Quarterly Portfolio Summary & Reliable Intraday Trade Plans - newser.com
Is AbCellera Biologics Inc. (8QQ) stock in buy zone after pullbackJuly 2025 Spike Watch & Long-Term Safe Return Strategies - newser.com
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):